Avanir Pharmaceuticals Announces Landmark ‘PRISM’ Pseudobulbar Affect Patient Registry

Avanir is launching a patient registry to determine the prevalence of pseudobulbar affect (PBA) in individuals with neurological conditions (preliminarily estimated to be about 2 million). The uncontrolled bouts of laughing and crying that characterize PBA have been reported in a subset of ALS patients. Avanir anticipates that the data from the registry will support additional clinical research efforts moving forward.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail